India, Sept. 19 -- Teva Pharmaceutical Industries Ltd. (TEVA), a generic drugs company, on Friday presented positive post-hoc data from the Phase 3 SOLARIS trial for TEV-'749 in treating schizophrenia. The results were presented at the Psych Congress in New Orleans, Louisiana.
Schizophrenia is a chronic, progressive, and debilitating mental disorder that affects a patient's thoughts and actions through delusions, hallucinations, and impaired cognition. Approximately 1% of the world's population will develop the disease at some point in their lives, with an estimated 2.2 million individuals affected in the U.S. alone. Long-term therapies may result in total or partial remission, yet over 80% of patients experience a relapse within the first...